Yeah, he made the statement that there were no risks, paused then added in that bad data would be a risk, changed that to someone dying, then went on to say there were no risk in the short term. So with a CEO making that statement, to me means no risks. Especially when we have 28/30 patients. If the last 2 patients were complete responders that would be significant, if they are non responders it will barely move the needle down. MCC is not priced in to the current stock, nor is the 1 year survival data. Honestly I don't even think interim P2 data is priced in.